E Vincent S Faustino1, Leslie J Raffini2, Sheila J Hanson3, Jill M Cholette4, Matthew G Pinto5, Simon Li5, Sarah B Kandil1, Marianne E Nellis6, Veronika Shabanova1, Cicero T Silva7, Joana A Tala8, Tara McPartland9, Philip C Spinella10. 1. Department of Pediatrics, Yale School of Medicine, New Haven, CT. 2. Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA. 3. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI. 4. Department of Pediatrics, University of Rochester Golisano Children's Hospital, Rochester, NY. 5. Department of Pediatrics, New York Medical College, Maria Fareri Children's Hospital, Valhalla, NY. 6. Department of Pediatrics, NY Presbyterian Hospital/Weill Cornell Medicine, New York, NY. 7. Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT. 8. Pediatric Intensive Care Unit, Yale-New Haven Children's Hospital, New Haven, CT. 9. Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT. 10. Department of Pediatrics, Washington University in St. Louis, St. Louis, MO.
Abstract
OBJECTIVES: We explored the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin against central venous catheter-associated deep venous thrombosis in critically ill children. DESIGN: Post hoc analysis of a Bayesian phase 2b randomized clinical trial. SETTING: Seven PICUs. PATIENTS: Children less than 18 years old with newly inserted central venous catheter. INTERVENTIONS: Enoxaparin started less than 24 hours after insertion of central venous catheter and adjusted to anti-Xa level of 0.2-0.5 international units/mL versus usual care. MEASUREMENTS AND MAIN RESULTS: Of 51 children randomized, 24 were infants less than 1 year old. Risk ratios of central venous catheter-associated deep venous thrombosis with prophylaxis with enoxaparin were 0.98 (95% credible interval, 0.37-2.44) in infants and 0.24 (95% credible interval, 0.04-0.82) in older children greater than or equal to 1 year old. Infants and older children achieved anti-Xa level greater than or equal to 0.2 international units/mL at comparable times. While central venous catheter was in situ, endogenous thrombin potential, a measure of thrombin generation, was 223.21 nM.min (95% CI, 8.78-437.64 nM.min) lower in infants. Factor VIII activity, a driver of thrombin generation, was also lower in infants by 45.1% (95% CI, 15.7-74.4%). Median minimum platelet count while central venous catheter was in situ was higher in infants by 39 × 103/mm3 (interquartile range, 17-61 × 103/mm3). Central venous catheter:vein ratio was not statistically different. Prophylaxis with enoxaparin was less efficacious against central venous catheter-associated deep venous thrombosis at lower factor VIII activity and at higher platelet count. CONCLUSIONS: The relatively lesser contribution of thrombin generation on central venous catheter-associated thrombus formation in critically ill infants potentially explains the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin.
OBJECTIVES: We explored the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin against central venous catheter-associated deep venous thrombosis in critically ill children. DESIGN: Post hoc analysis of a Bayesian phase 2b randomized clinical trial. SETTING: Seven PICUs. PATIENTS: Children less than 18 years old with newly inserted central venous catheter. INTERVENTIONS: Enoxaparin started less than 24 hours after insertion of central venous catheter and adjusted to anti-Xa level of 0.2-0.5 international units/mL versus usual care. MEASUREMENTS AND MAIN RESULTS: Of 51 children randomized, 24 were infants less than 1 year old. Risk ratios of central venous catheter-associated deep venous thrombosis with prophylaxis with enoxaparin were 0.98 (95% credible interval, 0.37-2.44) in infants and 0.24 (95% credible interval, 0.04-0.82) in older children greater than or equal to 1 year old. Infants and older children achieved anti-Xa level greater than or equal to 0.2 international units/mL at comparable times. While central venous catheter was in situ, endogenous thrombin potential, a measure of thrombin generation, was 223.21 nM.min (95% CI, 8.78-437.64 nM.min) lower in infants. Factor VIII activity, a driver of thrombin generation, was also lower in infants by 45.1% (95% CI, 15.7-74.4%). Median minimum platelet count while central venous catheter was in situ was higher in infants by 39 × 103/mm3 (interquartile range, 17-61 × 103/mm3). Central venous catheter:vein ratio was not statistically different. Prophylaxis with enoxaparin was less efficacious against central venous catheter-associated deep venous thrombosis at lower factor VIII activity and at higher platelet count. CONCLUSIONS: The relatively lesser contribution of thrombin generation on central venous catheter-associated thrombus formation in critically ill infants potentially explains the age-dependent heterogeneity in the efficacy of prophylaxis with enoxaparin.
Authors: Andreas Raue; Clemens Kreutz; Fabian Joachim Theis; Jens Timmer Journal: Philos Trans A Math Phys Eng Sci Date: 2012-12-31 Impact factor: 4.226
Authors: Ryan J Good; Melanie Levin; Susan Feder; Michele M Loi; John S Kim; Brian R Branchford; Angela S Czaja; Todd C Carpenter Journal: Pediatr Crit Care Med Date: 2020-12 Impact factor: 3.624
Authors: Cedric Manlhiot; Leonardo R Brandão; Judith Kwok; Stefan Kegel; Ines B Menjak; Caitlin L Carew; Anthony K Chan; Steven M Schwartz; V Ben Sivarajan; Christopher A Caldarone; Glen S Van Arsdell; Brian W McCrindle Journal: J Pediatr Date: 2012-04-17 Impact factor: 4.406
Authors: Paul Monagle; Carlos A Cuello; Caitlin Augustine; Mariana Bonduel; Leonardo R Brandão; Tammy Capman; Anthony K C Chan; Sheila Hanson; Christoph Male; Joerg Meerpohl; Fiona Newall; Sarah H O'Brien; Leslie Raffini; Heleen van Ommen; John Wiernikowski; Suzan Williams; Meha Bhatt; John J Riva; Yetiani Roldan; Nicole Schwab; Reem A Mustafa; Sara K Vesely Journal: Blood Adv Date: 2018-11-27
Authors: Jeffrey N Harr; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; Eduardo Gonzalez; Max V Wohlauer; Anirban Banerjee; Christopher C Silliman; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2013-03 Impact factor: 3.313
Authors: Romy M W Kremers; Rob J Wagenvoord; H Bas de Laat; Paul Monagle; H Coenraad Hemker; Vera Ignjatovic Journal: Thromb Haemost Date: 2016-01-28 Impact factor: 5.249